Publications (2009)
Tobacco and other diseases. In Tobacco: The Public Health Disaster of the Twentieth Century
Hackshaw AK
Second edition Oxford University Press 2009 (in press) (2009)
Trial design strategies for vascular-targeted therapy of ovarian cancer
Varughese M.A. and Ledermann J.A
Clinical Ovarian Cancer, 2(1): 2-5 (2009)
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized double-blind placebo-controlled trial
Lee SM, Woll P, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Alil K, Jitlal M, Hackshaw A
JNCI, 101(15): 1049-1057 (2009)
Randomized double-blind placebo-controlled trial of Thalidomide in combination with Gemcetabine and Carboplatin in advanced non-small-cell lung cancer
Lee SM, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A
JCO 27:5248-5254 (2009)
Fibrolamellar hepatocellular carcinoma - prolonged survival with multimodality therapy
Maniaci V, Davidson B, Rolles K, Dhillon P, Hackshaw A, Begent R, Meyer T
European Journal of Surgical Oncology 35: 617-621 (2009)
Positioning pemetrexed in the treatment of ovarian cancer
Ledermann JA and Stebbing J
Eur J Cancer, 45(8): 1330-2 (2009)
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma
Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, and Williams GH
Clin Cancer Res, 15: 2417-2425 (2009)
Assessment of two novel ventilatory surrogates for use in the delivery of gated/tracked radiotherapy for non-small cell lung cancer
Hughes S, McClelland J, Tarte S, Lawrence D, Ahmad S, Hawkes D and Landau D
Radiother Oncol, epub (2009)
Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer
Hackshaw A
Expert Opinion on Pharmacotherapy 10(16): 1-7 (2009)
Circulating Angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis
Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T
Endocrine-Related Cancer 16: 967–976 (2009)
Chemo-radiotherapy for locally advanced head and neck cancer: ten-year follow up of the UK Head and Neck (UKHAN1) trial
Tobias J, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A
Lancet Oncology 11: 66-74 (2009)
ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J
N Engl J Med. 362(14):1273-81 (2009)
Randomised Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma: Results from a UK NCRI Lymphoma Group Study
Hoskin P, Lowry L, Horwich A, Jack A, Mead G, Hancock B, Smith P, Qian W, Patrick P, Popova B, Pettitt P, Cunningham D, Pettengell P, Sweetenham J, Linch D and Johnson P
ISRCTN 64141244 JCO 5390-5396 (2009)
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO
Sharma R, Cunningham D, Smith P, Robertson G, Dent O and Clarke S.J
BMC Cancer 9:153 (2009)
